NL-OMON36409CompletedNot Applicable
Treatment optimization of cetuximab in patients with metastatic colorectal cancer based on tumour uptake of 89Zr-labeled cetuximab assessed by PET - Tumour uptake of 89Zr cetuximab
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 38
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •Advanced colorectal adenocarcinoma
- •Subjects must have been treated according to standard care with a fluoropyrimidine (e.g. fluorouracil or capecitabine), irinotecan, and oxaliplatin or had contra-indications to treatment with these drugs.
- •Tumour material must be tested wild type for the K-Ras gene.
- •Subjects have at least one measurable lesion outside the liver.
- •ECOG Performance Status of 0, 1 or 2
Exclusion Criteria
- •Previous exposure to an anti-EGFR therapy
- •Significant skin condition interfering with treatment
- •Insulin dependency
- •Concurrent anticancer chemotherapy, immunotherapy or investigational drug therapy during the study or within 4 weeks of the start of study drug.
- •Radiotherapy to the target lesions during study or within 4 weeks of the start of study drug. Palliative radiotherapy will be allowed.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Treatment optimization of cetuximab in patients with metastatic colorectal cancer based on tumour uptake of 89Zr-labeled cetuximab assessed by PET - COLO CETUXadvanced colorectal cancerMedDRA version: 12.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerEUCTR2010-021943-41-NLVU Medical Center38
Completed
Not Applicable
Optimalisatie van de behandeling van uitgezaaide darmkanker met cetuximab middels opname metingen van 89Zr gelabeld cetuximab mbv PET.metastatic colorectal cancer,NL-OMON25781VU Univeristy Medical Center25
Active, not recruiting
Phase 1
Cetuximab as salvage therapy in patients with neo wild-type RAS/RAF metastatic colorectal cancer. A Proof-of-concept studycolorectal cancerEUCTR2019-002115-26-FRInstitut Hospitalier Franco-Britanique72
Recruiting
Not Applicable
Optimalisatie van de behandeling met cetuximab voor patienten met uitgezaaide dikkedarm kanker door de opname van 89-zirconium gelabeld cetuximab te beoordelen middels PET-scaMetastatic colorecal adenocarcinoma, K-RAS and N-RAS wild type.NL-OMON26385VU University Medical Center (central site)UMC GroningenRadboud UMC85
Active, not recruiting
Not Applicable
Phase II study of cetuximab in combination with cisplatin-docetaxel in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): a biomarker-based assessment of activity. - NDon small cell lung cancerMedDRA version: 9.1Level: LLTClassification code 10001183MedDRA version: 9.1Level: LLTClassification code 10025038EUCTR2008-008387-27-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA